Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 484
Posts 81,491
Boards Moderated 21
Alias Born 09/05/02
160x600 placeholder
How to Find a Missing Tax Refund
What ever happened to my missing federal income-tax refund check?
European Markets Show Signs of Stress--2nd Update
Microsoft Gains Help Lead Tech's Advance
Treasury Bonds Pull Back for Second Straight Day
Will Free Data Become the Next Free Shipping?
Microsoft Braces for Another Nokia Hit--Earnings Preview
Procter & Gamble Looking at Margins, Brands--Earnings Preview
Pfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
U.S. Stocks Gain, but IBM Weighs on Dow
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 183195 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist